Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-154.21%
operating margin TTM
-115.53%
revenue TTM
24.38 Million
revenue per share TTM
2.52$
valuation ratios | |
|---|---|
| pe ratio | -0.10 |
| peg ratio | 0.00 |
| price to book ratio | -0.06 |
| price to sales ratio | 2.99 |
| enterprise value multiple | -3.38 |
| price fair value | -0.06 |
profitability ratios | |
|---|---|
| gross profit margin | 98.72% |
| operating profit margin | -115.53% |
| pretax profit margin | -154.32% |
| net profit margin | -154.21% |
| return on assets | -63.48% |
| return on equity | 192.77% |
| return on capital employed | -67.23% |
liquidity ratios | |
|---|---|
| current ratio | 3.12 |
| quick ratio | 3.12 |
| cash ratio | 1.04 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 45.75 |
| days of payables outstanding | 1,566.53 |
| cash conversion cycle | -1,520.78 |
| receivables turnover | 7.98 |
| payables turnover | 0.23 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.06 |
| debt equity ratio | -0.20 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | -0.26 |
| interest coverage | -2.89 |
| cash flow to debt ratio | -11.12 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1,162.94 |
| cash per share | 1,548.34 |
| operating cash flow per share | -1,158.87 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -11.12 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -284.98 |
Frequently Asked Questions
When was the last time Sutro Biopharma, Inc. (NASDAQ:STRO) reported earnings?
Sutro Biopharma, Inc. (STRO) published its most recent earnings results on 14-05-2026.
What is Sutro Biopharma, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Sutro Biopharma, Inc. (NASDAQ:STRO)'s trailing twelve months ROE is 192.77%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Sutro Biopharma, Inc. (STRO) currently has a ROA of -63.48%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did STRO's net profit margin stand at?
STRO reported a profit margin of -154.21% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is STRO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.12 in the most recent quarter. The quick ratio stood at 3.12, with a Debt/Eq ratio of -0.20.